课题基金 / 基金详情

Significance of inflammatory mediators in hepatocellular carcinoma

Significance of inflammatory mediators in hepatocellular carcinoma
炎症介质在肝细胞癌中的意义
批准号:
18591525
负责人:
ISHII Yuji
金额:
$2.53万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007

项目摘要

项目成果

ISHII Yuji的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Aim and Purpose : Endogenous cannabinoids (CBs) have been confirmed to play a role as early mediators, while high mobility group box-1 (HMGB-1) is known to be a late mediator in inflammatory response with inducing various physiologic actions. The aim of this study is to clarify a relationship between various inflammatory mediators including cytokines for the development and progression of HCC. Patients and Methods : For patients with hepatocellular carcinoma (HCC:n=45), liver cirrhosis (LC:n=23) or chronic hepatitis (CH:n=10) as well as in healthy volunteers (HV, n=34), the serum levels of CBs, 2-arachidonoylglycerol (2-AG) and anandamide (AEA) were measured by high performance liquid chromatography combined mass spectrometry (LC/MS). The serum levels of HMGB-1 and 6 inflammatory cytokines were measured by an enzyme-linked immunosorbent assay (HV:n=10, CH:n=5, LC:n=7, HCC:n=17). The expression of receptors for CBs. CBIR and CB2R as well as receptor for advanced glycation end product (RAGE) were examined by immunohistochemical analyses using the resected samples of HCC (n=23). Results : In patients with HCC, the mean level of 2-AG was 15.92 ± 7.30 ng/ml, which was significantly higher than those of the other groups (p< 0.01). The serum level of IL-8 was significantly higher in the advanced HCC group (p< 0.01). The mean level of HMGB-1 in HCC group was 5.51±2.92 ng/ml, which was significantly higher than those of the other groups (p <0.01). There existed a significant correlation between 2-AG and HMGB-1 (r=0.872, P< 0.01). In the immunohistochemical analysis of I-ICC, the expressions of CB1R and RAGE correlated with dedifferentiation of HCC. Conclusions : 2-AG, CBIR, IL-8 and FIMGB-1 seem to be associated with the development and progression of HCC. Blockade of such mediators may have potential for prevention and treatment of HCC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间: 2008
期刊:
影响因子: --
作者: [Yuji, Ishii, et. al., Yuj Ishii]
通讯作者: Yuj Ishii
DOI: --
发表时间: 2008
期刊:
影响因子: --
作者: [Yuji, Ishii, et. al., Yuji Ishii]
通讯作者: Yuji Ishii
Expression of receptor for advanced glycation end product in hepatocellular carcinoma by grading of tumor differentiation.
通过肿瘤分化分级评价肝细胞癌晚期糖基化终末产物受体的表达。
DOI: --
发表时间: 2008
期刊:
影响因子: --
作者: [Yuji, Ishii, et. al., Yuj Ishii, Ryusuke Ito]
通讯作者: Ryusuke Ito
Role of endogenous cannabinoidsas a novel marker of hepatocellular carcinoma
内源性大麻素作为肝细胞癌新标志物的作用
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [Yuji, Ishii, et. al., 石井 雄二, Yuji Ishii]
通讯作者: Yuji Ishii
8
    Bas i s stud i es on the appropr i ate usage of c l i n i ca I med i c i ne : i so form specificity of the functional interaction between drug metabolizing enzymes and the individual differences
    • 批准号:
      21590164
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2009
    • 负责人:
      ISHII Yuji
    • 依托单位:
    Basic Studies on the appropriate usage of clinical narcotics : the individual differences in the formation of morphine active metabolite which is not dependent on the genetic polymorphism
    • 批准号:
      19590147
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2007
    • 负责人:
      ISHII Yuji
    • 依托单位:
    Basic approach for good prescribing: Post-translational modulation of activities of drug-metabolizing enzymes
    • 批准号:
      17590128
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.3万
    • 财政年份:
      2005
    • 负责人:
      ISHII Yuji
    • 依托单位:
    Clinical Application of Anti-angiogenetic Therapy on Hepatocarcinogenesis and Hepatocellular carcinoma -With Special Reference to Matrix Metalloproteinases and Cytokines network-
    • 批准号:
      12671268
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.11万
    • 财政年份:
      2000
    • 负责人:
      ISHII Yuji
    • 依托单位:
    国内基金
    海外基金
    基于2-AG/CB2R信号通路调控小胶质细胞极化研究推拿按法抑制激痛点大脊髓背角痛觉敏化的机制
    • 批准号:
      --
    • 项目类别:
      面上项目
    • 资助金额:
      --
    • 批准年份:
      2024
    • 负责人:
      李江山
    • 依托单位:
    AOAH促进内源性大麻素2-AG生成调控银屑病免疫应答的机制研究
    • 批准号:
      32300772
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30万元
    • 批准年份:
      2023
    • 负责人:
      姜蔚
    • 依托单位:
    Akk菌通过上调2-AG改善NASH小鼠肠道屏障功能的作用机制研究
    • 批准号:
      LTGD23H030002
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2023
    • 负责人:
      虞思祎
    • 依托单位:
    靶向2-AG水解酶的活性小分子荧光探针的构建及其功能成像研究
    • 批准号:
      --
    • 项目类别:
      面上项目
    • 资助金额:
      54万元
    • 批准年份:
      2022
    • 负责人:
      邓慧
    • 依托单位: